Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

@article{Thomas2015SunitinibIP,
  title={Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.},
  author={Anish J Thomas and Arun Rajan and Arlene W. Berman and Yusuke Tomita and Christina E. Brzezniak and M R Lee and S Justin Lee and Alexander Ling and Aaron J Spittler and Corey Allan Carter and Udayan Guha and Yisong Wang and Eva Szab{\'o} and Paul S. Meltzer and Seth Steinberg and Jane B. Trepel and Patrick J. Loehrer and Guiseppe Giaccone},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 2},
  pages={177-86}
}
BACKGROUND No standard treatments are available for advanced thymic epithelial tumours after failure of platinum-based chemotherapy. We investigated the activity of sunitinib, an orally administered tyrosine kinase inhibitor. METHODS Between May 15, 2012, and Oct 2, 2013, we did an open-label phase 2 trial in patients with histologically confirmed chemotherapy-refractory thymic epithelial tumours. Patients were eligible if they had disease progression after at least one previous regimen of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS